Artivion, Inc. (AORT) stock
AORTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3021% above fair value
$19.10−0.30 (-1.55%)
Close on Nov 13, 2026Market cap $931.24MP/E –Yield –
Artivion r&d expenses
Research and development expenses are spending on new products and technology.
Artivion's R&D Expenses for the twelve months ending Sep 30, 2026 was $36.83M, up 25.8% year over year. For fiscal 2025 it was $30.99M, up 8.9% from the year before. Over ten years it grew 11.5% a year on average. The highest annual figure on record is $38.88M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.99M | +8.9% |
| FY2024 | Dec 31, 2024 | $28.45M | -0.9% |
| FY2023 | Dec 31, 2023 | $28.71M | -26.2% |
| FY2022 | Dec 31, 2022 | $38.88M | +9.4% |
| FY2021 | Dec 31, 2021 | $35.55M | +46.8% |
| FY2020 | Dec 31, 2020 | $24.21M | +5.4% |
| FY2019 | Dec 31, 2019 | $22.96M | -0.6% |
| FY2018 | Dec 31, 2018 | $23.10M | +18.7% |
| FY2017 | Dec 31, 2017 | $19.46M | +44.7% |
| FY2016 | Dec 31, 2016 | $13.45M | +28.8% |
| FY2015 | Dec 31, 2015 | $10.44M | +20.0% |
| FY2014 | Dec 31, 2014 | $8.70M | +2.9% |
| FY2013 | Dec 31, 2013 | $8.45M | +16.5% |
| FY2012 | Dec 31, 2012 | $7.26M | +5.2% |
| FY2011 | Dec 31, 2011 | $6.90M | +16.5% |
| FY2010 | Dec 31, 2010 | $5.92M | +12.9% |
| FY2009 | Dec 31, 2009 | $5.25M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.81M | +21.4% |
| Q2 FY2026 | Jun 30, 2026 | $9.06M | +28.2% |
| Q1 FY2026 | Mar 31, 2026 | $8.84M | +31.4% |
| Q4 FY2025 | Dec 31, 2025 | $9.12M | +23.2% |
| Q3 FY2025 | Sep 30, 2025 | $8.08M | +22.3% |
| Q2 FY2025 | Jun 30, 2025 | $7.06M | -5.8% |
| Q1 FY2025 | Mar 31, 2025 | $6.73M | -3.1% |
| Q4 FY2024 | Dec 31, 2024 | $7.40M | -3.2% |
| Q3 FY2024 | Sep 30, 2024 | $6.61M | +2.9% |
| Q2 FY2024 | Jun 30, 2024 | $7.50M | +1.1% |
| Q1 FY2024 | Mar 31, 2024 | $6.95M | -3.8% |
| Q4 FY2023 | Dec 31, 2023 | $7.65M | -7.9% |
| Q3 FY2023 | Sep 30, 2023 | $6.42M | -45.6% |
| Q2 FY2023 | Jun 30, 2023 | $7.42M | -14.2% |
| Q1 FY2023 | Mar 31, 2023 | $7.22M | -28.7% |
| Q4 FY2022 | Dec 31, 2022 | $8.30M | -12.2% |
| Q3 FY2022 | Sep 30, 2022 | $11.80M | +18.3% |
| Q2 FY2022 | Jun 30, 2022 | $8.65M | +3.4% |
| Q1 FY2022 | Mar 31, 2022 | $10.13M | +30.6% |
| Q4 FY2021 | Dec 31, 2021 | $9.46M | +43.9% |
| Q3 FY2021 | Sep 30, 2021 | $9.97M | +73.3% |
| Q2 FY2021 | Jun 30, 2021 | $8.36M | +51.4% |
| Q1 FY2021 | Mar 31, 2021 | $7.75M | +22.0% |
| Q4 FY2020 | Dec 31, 2020 | $6.57M | +23.8% |
| Q3 FY2020 | Sep 30, 2020 | $5.76M | -8.1% |
| Q2 FY2020 | Jun 30, 2020 | $5.52M | -5.5% |
| Q1 FY2020 | Mar 31, 2020 | $6.36M | +14.6% |
| Q4 FY2019 | Dec 31, 2019 | $5.31M | -21.7% |
| Q3 FY2019 | Sep 30, 2019 | $6.26M | +19.8% |
| Q2 FY2019 | Jun 30, 2019 | $5.84M | +2.1% |
| Q1 FY2019 | Mar 31, 2019 | $5.55M | +3.3% |
| Q4 FY2018 | Dec 31, 2018 | $6.78M | +6.6% |
| Q3 FY2018 | Sep 30, 2018 | $5.23M | +22.2% |
| Q2 FY2018 | Jun 30, 2018 | $5.72M | +21.0% |
| Q1 FY2018 | Mar 31, 2018 | $5.37M | +31.2% |
| Q4 FY2017 | Dec 31, 2017 | $6.36M | +65.5% |
| Q3 FY2017 | Sep 30, 2017 | $4.28M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.73M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.84M | – |
See a number that looks wrong?